Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT01158274 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This phase I clinical trial is studying the side effects and best dose of RO4929097 when given together with capecitabine in treating patients with refractory solid tumors. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving RO4929097 together with chemotherapy may kill more tumor cells.

NCT ID: NCT01158118 Completed - Multiple Myeloma Clinical Trials

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Start date: April 1, 2011
Phase: Phase 2
Study type: Interventional

This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling. The investigators believe that the two drugs together will provide enough stem cells for transplantation and may also reduce the risk of graft versus host disease.

NCT ID: NCT01156883 Completed - Leukemia Clinical Trials

Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia

LAL1308
Start date: April 2010
Phase: N/A
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with steroid therapy may kill more cancer cells. PURPOSE: This clinical trial is studying the side effects of combination chemotherapy in treating young adult patients with acute lymphoblastic leukemia.

NCT ID: NCT01154816 Completed - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01154439 Completed - Leukemia Clinical Trials

Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

AML1208
Start date: October 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as mitoxantrone hydrochloride, cytarabine, etoposide, and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving everolimus together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with mitoxantrone hydrochloride, cytarabine, etoposide, and idarubicin in treating older patients with newly diagnosed acute myeloid leukemia.

NCT ID: NCT01150669 Completed - Clinical trials for Childhood Acute Lymphoblastic Leukemia

Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia

Start date: July 2010
Phase: N/A
Study type: Observational

This research study is studying lestaurtinib with or with chemotherapy in samples from young patients with leukemia. Studying the effects of lestaurtinib with or without chemotherapy in cell samples from patients with cancer in the laboratory may help doctors learn more about the effects of this treatment on cancer cells. It may also help doctors identify biomarkers related to cancer.

NCT ID: NCT01150656 Completed - Leukemia Clinical Trials

Obatoclax Mesylate in Samples From Young Patients With Acute Myeloid Leukemia

Start date: June 2010
Phase: N/A
Study type: Observational

RATIONALE: Studying the effects of obatoclax mesylate in cell samples from patients with cancer in the laboratory may help doctors learn more about the effects of obatoclax mesylate on cancer cells. It may also help doctors identify biomarkers related to cancer. PURPOSE: This research study is studying obatoclax mesylate in samples from young patients with acute myeloid leukemia.

NCT ID: NCT01150058 Completed - Leukemia Clinical Trials

Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia

Start date: November 2010
Phase: N/A
Study type: Observational

RATIONALE: Studying cell samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer PURPOSE: This research study is studying drug biomarkers in cell samples from patients with acute myeloid leukemia.

NCT ID: NCT01149915 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the maximum tolerated dose, dose limiting toxicity, safety and tolerability of TH-302 in patients with acute leukemias, advanced phase chronic myelogenous leukemia (CML), high risk myelodysplastic syndromes, advanced myelofibrosis or relapsed/refractory chronic lymphocytic leukemia (CLL).

NCT ID: NCT01149668 Completed - Multiple Myeloma Clinical Trials

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO in subjects with lymphoma.